Cepheid (NASDAQ:CPHD) Strongly Positioned for 2011

Saying they're targeting the right trends heading into 2011, Cepheid (NASDAQ:CPHD) is positioned to take advantage going forward, according to Canaccord Genuity.

"We reiterate our rating on CPHD as it addresses the key trends for hospital labs, which includes bringing molecular testing in-house and consolidating existing molecular testing platforms...CPHD well positioned for 2011. 1) New tests (CT/GC, Flu) slated for launch; 2) Large, leverageable installed base of >1,700 instruments; 3) GM expansion; and 4) Profitability," said Canaccord.

Canaccord Genuity maintains a "Buy" rating on Cepheid, which closed Wednesday at $23.46, gaining $0.21, or 0.90 percent. Canaccord has a price target of $27 on them.